董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sarah Boyce | 女 | Director | 48 | 39.45万美元 | 未持股 | 2020-07-17 |
| Eric D. Hobbs | 男 | Chief Executive Officer and Director | 43 | 744.78万美元 | 未持股 | 2020-07-17 |
| Igor Khandros | -- | Director | 65 | 未披露 | 未持股 | 2020-07-17 |
| Gregory Lucier | 男 | Director | 56 | 未披露 | 未持股 | 2020-07-17 |
| James Rothman | 男 | Director | 69 | 25.00万美元 | 未持股 | 2020-07-17 |
| Michael Marks | 男 | Director | 69 | 未披露 | 未持股 | 2020-07-17 |
| Michael Moritz | 男 | Director | 65 | 未披露 | 未持股 | 2020-07-17 |
| Elizabeth Nelson | 女 | Director | 59 | 62.13万美元 | 未持股 | 2020-07-17 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Eric D. Hobbs | 男 | Chief Executive Officer and Director | 43 | 744.78万美元 | 未持股 | 2020-07-17 |
| Shaun M. Holt | 男 | Chief Financial Officer | 42 | 66.93万美元 | 未持股 | 2020-07-17 |
| Keith J. Breinlinger | 男 | Chief Technology Officer | 46 | 115.51万美元 | 未持股 | 2020-07-17 |
| Stuart L. Merkadeau | 男 | General Counsel | 59 | 未披露 | 未持股 | 2020-07-17 |
董事简历
中英对照 | 中文 | 英文- Sarah Boyce
-
Sarah Boyce在2015年1月加入Isis担任我们公司的首席商务官。在加入Isis之前（2012-2014年）她是Forest Laboratories股份有限公司（Forest Laboratories, Inc）副总裁和国际商务战略和运营负责人。2010-2011年她是Alexion Pharmaceuticals副总裁和肾脏病治疗领域的全球负责人。2000-2010年她在Novartis Group AG担任不同的职位，包括副总裁，儿科与专业的全球项目负责人。在那之前，她在Bayer Pharmaceuticals and Roche担任不同职位。
Sarah Boyce has served as a member of our board of directors since August 2019. Ms. Boyce has served as President and Chief Executive Officer of Avidity Biosciences LLC, a privately-held biotechnology company, since October 2019. Previously, Ms. Boyce served as the President and served on the board of directors of Akcea Therapeutics, Inc., a publicly-traded biopharmaceutical company, from April 2018 to September 2019. Before that, Ms. Boyce was the Chief Business Officer of Ionis Pharmaceuticals, Inc., a publicly-traded biotechnology company, from January 2015 to April 2018. Prior to joining Ionis, Ms. Boyce was Vice President, Head of International Business Strategy and Operations at Forest Laboratories, Inc., a publicly-traded pharmaceutical company that was acquired by Actavis Pharma, Inc. from 2012 to 2014. She was Vice President, Global Head Nephrology Therapeutics Area of Alexion Pharmaceuticals Inc., a publicly-traded pharmaceutical company, from 2010 to 2011. She held various positions at Novartis Group AG, a publicly-traded Swiss healthcare company, including Vice President, Global Program Head, Pediatric and Specialty from 2000 to 2010. Ms. Boyce currently serves on the board of directors of Avidity Biosciences LLC, a privately-held biotechnology company and Ligand Pharmaceuticals Incorporated, a publicly-traded biopharmaceutical company. Ms. Boyce received her B.S. in Microbiology from the University of Manchester, England. - Sarah Boyce在2015年1月加入Isis担任我们公司的首席商务官。在加入Isis之前（2012-2014年）她是Forest Laboratories股份有限公司（Forest Laboratories, Inc）副总裁和国际商务战略和运营负责人。2010-2011年她是Alexion Pharmaceuticals副总裁和肾脏病治疗领域的全球负责人。2000-2010年她在Novartis Group AG担任不同的职位，包括副总裁，儿科与专业的全球项目负责人。在那之前，她在Bayer Pharmaceuticals and Roche担任不同职位。
- Sarah Boyce has served as a member of our board of directors since August 2019. Ms. Boyce has served as President and Chief Executive Officer of Avidity Biosciences LLC, a privately-held biotechnology company, since October 2019. Previously, Ms. Boyce served as the President and served on the board of directors of Akcea Therapeutics, Inc., a publicly-traded biopharmaceutical company, from April 2018 to September 2019. Before that, Ms. Boyce was the Chief Business Officer of Ionis Pharmaceuticals, Inc., a publicly-traded biotechnology company, from January 2015 to April 2018. Prior to joining Ionis, Ms. Boyce was Vice President, Head of International Business Strategy and Operations at Forest Laboratories, Inc., a publicly-traded pharmaceutical company that was acquired by Actavis Pharma, Inc. from 2012 to 2014. She was Vice President, Global Head Nephrology Therapeutics Area of Alexion Pharmaceuticals Inc., a publicly-traded pharmaceutical company, from 2010 to 2011. She held various positions at Novartis Group AG, a publicly-traded Swiss healthcare company, including Vice President, Global Program Head, Pediatric and Specialty from 2000 to 2010. Ms. Boyce currently serves on the board of directors of Avidity Biosciences LLC, a privately-held biotechnology company and Ligand Pharmaceuticals Incorporated, a publicly-traded biopharmaceutical company. Ms. Boyce received her B.S. in Microbiology from the University of Manchester, England.
- Eric D. Hobbs
-
EricD.Hobbs自2017年3月以来一直担任我们的董事会成员和首席执行官。此前，霍布斯博士曾于2016年3月至2017年3月担任我们的高级副总裁，运营和消耗品，于2015年2月至2016年3月担任我们的Vice President，运营和消耗品，并于2013年5月至2015年2月担任研究与开发高级总监。在Berkeley Lights之前，霍布斯博士在FormFactor公司或FormFactor公司（一家公开上市的半导体技术公司）担任越来越重要的职务，最近担任产品管理高级主管。Hobbs博士在加州圣玛丽学院（Saint Mary&8217；s College of California）获得文科学士学位，并辅修数学和物理，在南加州大学（University of Southern California）获得机械工程学士学位，在加州大学伯克利分校（University of California，Berkeley）获得微机电系统机械工程硕士学位和博士学位。
Eric D. Hobbs has served as a member of our board of directors and as our Chief Executive Officer since March 2017. Previously, Dr. Hobbs served as our Senior Vice President, Operations and Consumables, from March 2016 to March 2017 as our Vice President, Operations and Consumables, from February 2015 to March 2016 and as Senior Director, Research and Development, from May 2013 until February 2015. Prior to Berkeley Lights, Dr. Hobbs held roles of increasing responsibility at FormFactor Inc., or FormFactor, a publicly-traded semiconductor technology company, serving most recently as Senior Director of Product Management. Dr. Hobbs received his B.A. in Liberal Arts, with minors in Mathematics and Physics from Saint Mary’s College of California, his B.S. in Mechanical Engineering from the University of Southern California, and his M.S. and Ph.D. in Mechanical Engineering, Microelectromechanical Systems, from the University of California, Berkeley. - EricD.Hobbs自2017年3月以来一直担任我们的董事会成员和首席执行官。此前，霍布斯博士曾于2016年3月至2017年3月担任我们的高级副总裁，运营和消耗品，于2015年2月至2016年3月担任我们的Vice President，运营和消耗品，并于2013年5月至2015年2月担任研究与开发高级总监。在Berkeley Lights之前，霍布斯博士在FormFactor公司或FormFactor公司（一家公开上市的半导体技术公司）担任越来越重要的职务，最近担任产品管理高级主管。Hobbs博士在加州圣玛丽学院（Saint Mary&8217；s College of California）获得文科学士学位，并辅修数学和物理，在南加州大学（University of Southern California）获得机械工程学士学位，在加州大学伯克利分校（University of California，Berkeley）获得微机电系统机械工程硕士学位和博士学位。
- Eric D. Hobbs has served as a member of our board of directors and as our Chief Executive Officer since March 2017. Previously, Dr. Hobbs served as our Senior Vice President, Operations and Consumables, from March 2016 to March 2017 as our Vice President, Operations and Consumables, from February 2015 to March 2016 and as Senior Director, Research and Development, from May 2013 until February 2015. Prior to Berkeley Lights, Dr. Hobbs held roles of increasing responsibility at FormFactor Inc., or FormFactor, a publicly-traded semiconductor technology company, serving most recently as Senior Director of Product Management. Dr. Hobbs received his B.A. in Liberal Arts, with minors in Mathematics and Physics from Saint Mary’s College of California, his B.S. in Mechanical Engineering from the University of Southern California, and his M.S. and Ph.D. in Mechanical Engineering, Microelectromechanical Systems, from the University of California, Berkeley.
- Igor Khandros
-
Igor Khandros自2011年以来一直担任我们的董事会成员。Khandros博士自2017年10月起担任私人生物技术公司Nutcracker Therapeutics，Inc.的首席执行官。Khandros博士是我们的联合创始人之一，并于2011年至2017年3月担任我们的首席执行官。此前，Khandros博士创立了两家上市公司FormFactor和TesseraTechnologies，Inc.（一家技术许可公司），并担任其董事。Khandros博士在乌克兰基辅的基辅理工学院（Kiev Polytechnic Institute）获得中国中冶工程硕士学位，并在史蒂文斯理工学院（Stevens Institute of Technology）获得冶金博士学位。
Igor Khandros has served as a member of our board of directors since 2011. Dr. Khandros has served as Chief Executive Officer of Nutcracker Therapeutics, Inc., a privately-held biotechnology company, since October 2017. Dr. Khandros is one of our Co-Founders and, from 2011 to March 2017 served as our Chief Executive Officer. Previously, Dr. Khandros founded and served on the boards of directors of two publicly-traded companies, FormFactor and Tessera Technologies, Inc., a technology licensing company. Dr. Khandros received an M.S.-equivalent degree in Metallurgical Engineering from Kiev Polytechnic Institute in Kiev, Ukraine, and a Ph.D. in Metallurgy from Stevens Institute of Technology. - Igor Khandros自2011年以来一直担任我们的董事会成员。Khandros博士自2017年10月起担任私人生物技术公司Nutcracker Therapeutics，Inc.的首席执行官。Khandros博士是我们的联合创始人之一，并于2011年至2017年3月担任我们的首席执行官。此前，Khandros博士创立了两家上市公司FormFactor和TesseraTechnologies，Inc.（一家技术许可公司），并担任其董事。Khandros博士在乌克兰基辅的基辅理工学院（Kiev Polytechnic Institute）获得中国中冶工程硕士学位，并在史蒂文斯理工学院（Stevens Institute of Technology）获得冶金博士学位。
- Igor Khandros has served as a member of our board of directors since 2011. Dr. Khandros has served as Chief Executive Officer of Nutcracker Therapeutics, Inc., a privately-held biotechnology company, since October 2017. Dr. Khandros is one of our Co-Founders and, from 2011 to March 2017 served as our Chief Executive Officer. Previously, Dr. Khandros founded and served on the boards of directors of two publicly-traded companies, FormFactor and Tessera Technologies, Inc., a technology licensing company. Dr. Khandros received an M.S.-equivalent degree in Metallurgical Engineering from Kiev Polytechnic Institute in Kiev, Ukraine, and a Ph.D. in Metallurgy from Stevens Institute of Technology.
- Gregory Lucier
-
Gregory Lucier自2020年6月以来一直担任我们的董事会成员。Lucier先生自2019年4月起担任Corza Health，Inc.（一家私人控股公司，专注于收购公司和资产，作为建立市场领先的梦百合业务战略的一部分）的首席执行官。在此之前，他曾于2015年6月至2018年12月担任上市医疗设备公司Nuvasive，Inc.的首席执行官。在加入NuVasive之前，Lucier先生于2003年5月至2014年2月担任Life Technologies Corporation（前身为Invitrogen Corporation，一家上市的全球生物技术公司）的董事长兼首席执行官，该公司于2014年2月被赛默飞世尔科技公司收购。在此之前，Lucier先生是通用电气公司的一名公司官员，他在该公司担任过各种领导职务。Lucier先生是Nuvasive，Inc.公司（一家上市医疗设备公司）和Epic Sciences公司（一家私营生物技术公司）的董事会主席，并曾担任Catalent，Inc.公司（一家上市制药公司）的董事，自2015年4月起，他曾于2003年5月至2014年2月任职于Life Technologies Corporation的董事会，该公司是一家上市医疗设备公司，2009年8月至2015年3月被出售给Becton Dickinson和Invuity，Inc.从2014年10月到2018年10月出售给Stryker。Lucier先生在宾夕法尼亚州立大学（Pennsylvania State University）获得工业工程学士学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
Gregory Lucier has served as a member of our board of directors since June 2020. Mr. Lucier has served as the Chief Executive Officer of Corza Health, Inc., a privately-held company focused on acquiring companies and assets as part of a strategy to build a market-leading healthcare business, since April 2019. Prior to that, he served as Chief Executive Officer of NuVasive, Inc., a publicly-traded medical device company, from June 2015 to December 2018. Before joining Nuvasive, Mr. Lucier was Chairman and Chief Executive Officer of Life Technologies Corporation formerly Invitrogen Corporation, a publicly-traded global biotechnology company, from May 2003 until it was acquired by Thermo Fisher Scientific Inc. in February 2014. Prior to that, Mr. Lucier was a corporate officer at General Electric Company, where he served in a variety of leadership roles. Mr. Lucier is Chairman of the boards of directors of Nuvasive, Inc., a publicly traded medical device company, and Epic Sciences, a privately-held biotechnology company, and has served as a director of Catalent, Inc., a publicly-traded pharmaceutical company, since April 2015 and previously served on the boards of directors of Life Technologies Corporation from May 2003 to February 2014 of CareFusion Corporation, a publicly-traded medical device company, from August 2009 until its sale to Becton Dickinson in March 2015 and of Invuity, Inc. from October 2014 until its sale to Stryker in October 2018. Mr. Lucier received his B.S. in Industrial Engineering from Pennsylvania State University and his M.B.A. from Harvard Business School. - Gregory Lucier自2020年6月以来一直担任我们的董事会成员。Lucier先生自2019年4月起担任Corza Health，Inc.（一家私人控股公司，专注于收购公司和资产，作为建立市场领先的梦百合业务战略的一部分）的首席执行官。在此之前，他曾于2015年6月至2018年12月担任上市医疗设备公司Nuvasive，Inc.的首席执行官。在加入NuVasive之前，Lucier先生于2003年5月至2014年2月担任Life Technologies Corporation（前身为Invitrogen Corporation，一家上市的全球生物技术公司）的董事长兼首席执行官，该公司于2014年2月被赛默飞世尔科技公司收购。在此之前，Lucier先生是通用电气公司的一名公司官员，他在该公司担任过各种领导职务。Lucier先生是Nuvasive，Inc.公司（一家上市医疗设备公司）和Epic Sciences公司（一家私营生物技术公司）的董事会主席，并曾担任Catalent，Inc.公司（一家上市制药公司）的董事，自2015年4月起，他曾于2003年5月至2014年2月任职于Life Technologies Corporation的董事会，该公司是一家上市医疗设备公司，2009年8月至2015年3月被出售给Becton Dickinson和Invuity，Inc.从2014年10月到2018年10月出售给Stryker。Lucier先生在宾夕法尼亚州立大学（Pennsylvania State University）获得工业工程学士学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
- Gregory Lucier has served as a member of our board of directors since June 2020. Mr. Lucier has served as the Chief Executive Officer of Corza Health, Inc., a privately-held company focused on acquiring companies and assets as part of a strategy to build a market-leading healthcare business, since April 2019. Prior to that, he served as Chief Executive Officer of NuVasive, Inc., a publicly-traded medical device company, from June 2015 to December 2018. Before joining Nuvasive, Mr. Lucier was Chairman and Chief Executive Officer of Life Technologies Corporation formerly Invitrogen Corporation, a publicly-traded global biotechnology company, from May 2003 until it was acquired by Thermo Fisher Scientific Inc. in February 2014. Prior to that, Mr. Lucier was a corporate officer at General Electric Company, where he served in a variety of leadership roles. Mr. Lucier is Chairman of the boards of directors of Nuvasive, Inc., a publicly traded medical device company, and Epic Sciences, a privately-held biotechnology company, and has served as a director of Catalent, Inc., a publicly-traded pharmaceutical company, since April 2015 and previously served on the boards of directors of Life Technologies Corporation from May 2003 to February 2014 of CareFusion Corporation, a publicly-traded medical device company, from August 2009 until its sale to Becton Dickinson in March 2015 and of Invuity, Inc. from October 2014 until its sale to Stryker in October 2018. Mr. Lucier received his B.S. in Industrial Engineering from Pennsylvania State University and his M.B.A. from Harvard Business School.
- James Rothman
-
James Rothman自2016年5月以来一直担任我们的董事会成员。Rothman博士从2008年开始一直担任耶鲁大学（Yale University）的教员，在那里他担任细胞生物学的斯特林教授，耶鲁医学院（Yale School of Medicine）细胞生物学系的主席，并且是纳米生物学研究所（Nanobiology Institute）的主任和创始人。Rothman博士从2001年到2013年担任GE梦百合的首席科学官。此前，他曾创立Memorial Sloan-Kettering Cancer Center的细胞生物化学和生物物理系，并担任其主席（从1991年到2004年），在那里他曾担任Paul A.Marks主席，也曾担任副主席。此前，Rothman从2004年到2008年担任Columbia University生理学和细胞生物物理系WU化学生物学教授以及Columbia University’；S Sulzberger基因组中心主任。Rothman博士因其在囊泡贩运方面的工作而被授予2013年诺贝尔生理学或医学奖。Rothman博士目前在各种私人生物技术公司的董事会任职。Rothman博士在耶鲁大学（Yale College）获得物理学学士学位，在哈佛大学（Harvard University）获得生物化学博士学位。
James Rothman has served as a member of our board of directors since May 2016. Dr. Rothman has been a faculty member at Yale University since 2008 where he serves as the Sterling Professor of Cell Biology, Chairman of the Yale School of Medicine’s Department of Cell Biology and is the Director and founder of the Nanobiology Institute. Dr. Rothman served as Chief Scientific Officer of GE Healthcare, from 2001 to 2013. Previously, Dr. Rothman founded and chaired the Department of Cellular Biochemistry and Biophysics at Memorial Sloan-Kettering Cancer Center from 1991 until 2004 where he held the Paul A. Marks Chair and served as Vice-Chairman. Previously, Dr. Rothman was the Wu Professor of Chemical Biology in the Department of Physiology and Cellular Biophysics at Columbia University and Director of Columbia University’s Sulzberger Genome Center, from 2004 to 2008. Dr. Rothman was awarded the 2013 Nobel Prize in Physiology or Medicine, for his work on vesicle trafficking. Dr. Rothman currently serves on the boards of directors for various private biotechnology companies. Dr. Rothman received his B.A. in Physics from Yale College and his Ph.D. in Biochemistry from Harvard University. - James Rothman自2016年5月以来一直担任我们的董事会成员。Rothman博士从2008年开始一直担任耶鲁大学（Yale University）的教员，在那里他担任细胞生物学的斯特林教授，耶鲁医学院（Yale School of Medicine）细胞生物学系的主席，并且是纳米生物学研究所（Nanobiology Institute）的主任和创始人。Rothman博士从2001年到2013年担任GE梦百合的首席科学官。此前，他曾创立Memorial Sloan-Kettering Cancer Center的细胞生物化学和生物物理系，并担任其主席（从1991年到2004年），在那里他曾担任Paul A.Marks主席，也曾担任副主席。此前，Rothman从2004年到2008年担任Columbia University生理学和细胞生物物理系WU化学生物学教授以及Columbia University’；S Sulzberger基因组中心主任。Rothman博士因其在囊泡贩运方面的工作而被授予2013年诺贝尔生理学或医学奖。Rothman博士目前在各种私人生物技术公司的董事会任职。Rothman博士在耶鲁大学（Yale College）获得物理学学士学位，在哈佛大学（Harvard University）获得生物化学博士学位。
- James Rothman has served as a member of our board of directors since May 2016. Dr. Rothman has been a faculty member at Yale University since 2008 where he serves as the Sterling Professor of Cell Biology, Chairman of the Yale School of Medicine’s Department of Cell Biology and is the Director and founder of the Nanobiology Institute. Dr. Rothman served as Chief Scientific Officer of GE Healthcare, from 2001 to 2013. Previously, Dr. Rothman founded and chaired the Department of Cellular Biochemistry and Biophysics at Memorial Sloan-Kettering Cancer Center from 1991 until 2004 where he held the Paul A. Marks Chair and served as Vice-Chairman. Previously, Dr. Rothman was the Wu Professor of Chemical Biology in the Department of Physiology and Cellular Biophysics at Columbia University and Director of Columbia University’s Sulzberger Genome Center, from 2004 to 2008. Dr. Rothman was awarded the 2013 Nobel Prize in Physiology or Medicine, for his work on vesicle trafficking. Dr. Rothman currently serves on the boards of directors for various private biotechnology companies. Dr. Rothman received his B.A. in Physics from Yale College and his Ph.D. in Biochemistry from Harvard University.
- Michael Marks
-
Michael Marks ，他任职我们的董事会（2009年8月以来）。他于2007年3月创立Riverwood Capital公司（风险资本公司），并自此担任合伙人。从2007年1月到2007年12月，他曾担任高级顾问。从2006年1月到2006年12月，他担任Kohlberg Kravis Roberts公司的合伙人。他曾担任Flextronics International公司的主席（从2006年1月到2007年1月）、首席执行官（从2004年1月到2005年12月）。他也曾任职SanDisk Corporation（上市闪存数据存储产品的供应商）和Schlumberger Limited公司（上市油田服务提供商）的董事会。他也任职于Virtual Instruments公司（私立公司）、Aptina Imaging Technologies公司（私立公司）、 V Foundation for Cancer Research（非营利组织）、National Parks Conservation Association（非营利组织）的董事会。他持有哈佛大学商学院（Harvard Business School）的工商管理硕士学位，以及Oberlin College的学士学位和硕士学位。
Michael Marks has served as a member of our board of directors since April 2014. Mr. Marks has served as Founding Managing Partner of WRVI Capital, a technology venture capital fund, since 2014 as Founding Managing Partner of WRV Capital, a technology venture capital fund, since 2014 and as Chief Executive Officer, Chairman and Founder of Katerra, Inc., or Katerra, a technology company, since March 2015. Previously, Mr. Marks served as a founding partner of Paxion Capital, a private partnership, from March 2015 until March 2020 was a Founding Partner of Riverwood Capital, a private equity firm, from March 2007 until May 2019 and a Partner and Senior Advisor at Kohlberg Kravis Roberts & Co., a private equity firm, from 2006 to 2007. Prior to these roles, Mr. Marks served as Chief Executive Officer of Flextronics from 1994 until 2006 and as member of its board of directors from 1994 to 2007. Mr. Marks currently serves on the board of directors of several companies, including Katerra, Lolli & Pops, a privately-held candy manufacturing company, Bossa Nova, a privately-held robotics company, The Melt, a restaurant chain and H2O.ai, a software company. Mr. Marks previously served on the board of directors of publicly-traded companies, Schlumberger Limited, an oilfield services company, from January 2015 to July 2019 GoPro, Inc., a technology company from February 2011 to April 2017 and SanDisk Corporation, a manufacturer of flash memory products from 2003 to September 2016. Mr. Marks received his B.A. and M.A. in Psychology from Oberlin College and his M.B.A. from Harvard Business School. - Michael Marks ，他任职我们的董事会（2009年8月以来）。他于2007年3月创立Riverwood Capital公司（风险资本公司），并自此担任合伙人。从2007年1月到2007年12月，他曾担任高级顾问。从2006年1月到2006年12月，他担任Kohlberg Kravis Roberts公司的合伙人。他曾担任Flextronics International公司的主席（从2006年1月到2007年1月）、首席执行官（从2004年1月到2005年12月）。他也曾任职SanDisk Corporation（上市闪存数据存储产品的供应商）和Schlumberger Limited公司（上市油田服务提供商）的董事会。他也任职于Virtual Instruments公司（私立公司）、Aptina Imaging Technologies公司（私立公司）、 V Foundation for Cancer Research（非营利组织）、National Parks Conservation Association（非营利组织）的董事会。他持有哈佛大学商学院（Harvard Business School）的工商管理硕士学位，以及Oberlin College的学士学位和硕士学位。
- Michael Marks has served as a member of our board of directors since April 2014. Mr. Marks has served as Founding Managing Partner of WRVI Capital, a technology venture capital fund, since 2014 as Founding Managing Partner of WRV Capital, a technology venture capital fund, since 2014 and as Chief Executive Officer, Chairman and Founder of Katerra, Inc., or Katerra, a technology company, since March 2015. Previously, Mr. Marks served as a founding partner of Paxion Capital, a private partnership, from March 2015 until March 2020 was a Founding Partner of Riverwood Capital, a private equity firm, from March 2007 until May 2019 and a Partner and Senior Advisor at Kohlberg Kravis Roberts & Co., a private equity firm, from 2006 to 2007. Prior to these roles, Mr. Marks served as Chief Executive Officer of Flextronics from 1994 until 2006 and as member of its board of directors from 1994 to 2007. Mr. Marks currently serves on the board of directors of several companies, including Katerra, Lolli & Pops, a privately-held candy manufacturing company, Bossa Nova, a privately-held robotics company, The Melt, a restaurant chain and H2O.ai, a software company. Mr. Marks previously served on the board of directors of publicly-traded companies, Schlumberger Limited, an oilfield services company, from January 2015 to July 2019 GoPro, Inc., a technology company from February 2011 to April 2017 and SanDisk Corporation, a manufacturer of flash memory products from 2003 to September 2016. Mr. Marks received his B.A. and M.A. in Psychology from Oberlin College and his M.B.A. from Harvard Business School.
- Michael Moritz
-
Michael Moritz，自2007年12月起担任董事，兼任提名与治理委员会成员；自1986年起成为Sequoia Capital（风险资本基金）的一员；此前担任Time Warner的多个职位，是Technologic Partners（技术简报和会议公司）的创始人；自2003年2月起担任Green Dot Corporation（金融服务上市公司）的董事，兼任赔偿委员会成员；2011年1月起担任LinkedIn Corporation（在线专业网络上市公司）的董事；此前担任Flextronics Ltd., Google Inc., PayPal, Inc., Yahoo! Inc. 和Zappos.com, Inc.的董事。他获得了The Wharton School, University of Pennsylvania的工商管理硕士学位，和the University of Oxford的硕士学位。
Michael Moritz has served as a member of our board of directors since April 2015. Mr. Moritz has been a Managing Partner of Sequoia Capital, a venture capital fund, since 1986. Mr. Moritz currently serves on the board of directors of numerous private companies, including Stripe, Inc., a financial technology company, Instacart, a grocery delivery technology company, Charlotte Tilbury, a cosmetics company, GameFly, a technology company, Klarna, a financial technology company, and Group Nine Media, a digital media company. Previously, Mr. Moritz served on the board of directors of LinkedIn Corporation, a publicly-traded professional networking company, from 2011 to June 2016 and Green Dot Corporation, a publicly-traded financial technology company, from 2003 to May 2016. Mr. Moritz received his M.A. in History from Christ Church, Oxford. - Michael Moritz，自2007年12月起担任董事，兼任提名与治理委员会成员；自1986年起成为Sequoia Capital（风险资本基金）的一员；此前担任Time Warner的多个职位，是Technologic Partners（技术简报和会议公司）的创始人；自2003年2月起担任Green Dot Corporation（金融服务上市公司）的董事，兼任赔偿委员会成员；2011年1月起担任LinkedIn Corporation（在线专业网络上市公司）的董事；此前担任Flextronics Ltd., Google Inc., PayPal, Inc., Yahoo! Inc. 和Zappos.com, Inc.的董事。他获得了The Wharton School, University of Pennsylvania的工商管理硕士学位，和the University of Oxford的硕士学位。
- Michael Moritz has served as a member of our board of directors since April 2015. Mr. Moritz has been a Managing Partner of Sequoia Capital, a venture capital fund, since 1986. Mr. Moritz currently serves on the board of directors of numerous private companies, including Stripe, Inc., a financial technology company, Instacart, a grocery delivery technology company, Charlotte Tilbury, a cosmetics company, GameFly, a technology company, Klarna, a financial technology company, and Group Nine Media, a digital media company. Previously, Mr. Moritz served on the board of directors of LinkedIn Corporation, a publicly-traded professional networking company, from 2011 to June 2016 and Green Dot Corporation, a publicly-traded financial technology company, from 2003 to May 2016. Mr. Moritz received his M.A. in History from Christ Church, Oxford.
- Elizabeth Nelson
-
Elizabeth Nelson，2012年起担任Nokia 董事会成员。审计委员会及人事委员会成员。University of Pennsylvania, the United States. BS沃顿商学院金融MBA。美国乔治敦大学外交事务学士。1997-2005年，担任Macromedia公司的执行副总裁兼首席财务官。1996-1997年担任Macromedia公司企业发展副总裁。1988-1996年在惠普公司担任公司发展和国际金融的各种职务。国际发展协会理事会主席。2013-2019年，担任Zendesk Inc的独立首席董事和审计委员会主席。2013-2017年担任Pandora Media的董事会成员。
Elizabeth Nelson, Nokia Board member since 2012. Member of the Audit Committee and the Personnel Committee.MBA Finance, the Wharton School, University of Pennsylvania, the United States. BS (Foreign Service), Georgetown University, the United States.Executive Vice President and Chief Financial Officer, Macromedia, Inc. 1997-2005. Vice President, Corporate Development, Macromedia, Inc. 1996-1997. Various roles in Corporate Development and International Finance, Hewlett-Packard Company 1988-1996.Chair of the Board of Directors of DAI. Independent Member of the Board of Directors and Chair of the Audit Committee of Upwork Inc.Independent Member of the Board of Directors and Chair of the Audit Committee of Berkeley Lights, Inc.Independent Lead Director and Chair of the Audit Committee of Zendesk Inc 2013-2019. Member of the Board of Directors of Pandora Media 2013-2017. - Elizabeth Nelson，2012年起担任Nokia 董事会成员。审计委员会及人事委员会成员。University of Pennsylvania, the United States. BS沃顿商学院金融MBA。美国乔治敦大学外交事务学士。1997-2005年，担任Macromedia公司的执行副总裁兼首席财务官。1996-1997年担任Macromedia公司企业发展副总裁。1988-1996年在惠普公司担任公司发展和国际金融的各种职务。国际发展协会理事会主席。2013-2019年，担任Zendesk Inc的独立首席董事和审计委员会主席。2013-2017年担任Pandora Media的董事会成员。
- Elizabeth Nelson, Nokia Board member since 2012. Member of the Audit Committee and the Personnel Committee.MBA Finance, the Wharton School, University of Pennsylvania, the United States. BS (Foreign Service), Georgetown University, the United States.Executive Vice President and Chief Financial Officer, Macromedia, Inc. 1997-2005. Vice President, Corporate Development, Macromedia, Inc. 1996-1997. Various roles in Corporate Development and International Finance, Hewlett-Packard Company 1988-1996.Chair of the Board of Directors of DAI. Independent Member of the Board of Directors and Chair of the Audit Committee of Upwork Inc.Independent Member of the Board of Directors and Chair of the Audit Committee of Berkeley Lights, Inc.Independent Lead Director and Chair of the Audit Committee of Zendesk Inc 2013-2019. Member of the Board of Directors of Pandora Media 2013-2017.
高管简历
中英对照 | 中文 | 英文- Eric D. Hobbs
EricD.Hobbs自2017年3月以来一直担任我们的董事会成员和首席执行官。此前，霍布斯博士曾于2016年3月至2017年3月担任我们的高级副总裁，运营和消耗品，于2015年2月至2016年3月担任我们的Vice President，运营和消耗品，并于2013年5月至2015年2月担任研究与开发高级总监。在Berkeley Lights之前，霍布斯博士在FormFactor公司或FormFactor公司（一家公开上市的半导体技术公司）担任越来越重要的职务，最近担任产品管理高级主管。Hobbs博士在加州圣玛丽学院（Saint Mary&8217；s College of California）获得文科学士学位，并辅修数学和物理，在南加州大学（University of Southern California）获得机械工程学士学位，在加州大学伯克利分校（University of California，Berkeley）获得微机电系统机械工程硕士学位和博士学位。
Eric D. Hobbs has served as a member of our board of directors and as our Chief Executive Officer since March 2017. Previously, Dr. Hobbs served as our Senior Vice President, Operations and Consumables, from March 2016 to March 2017 as our Vice President, Operations and Consumables, from February 2015 to March 2016 and as Senior Director, Research and Development, from May 2013 until February 2015. Prior to Berkeley Lights, Dr. Hobbs held roles of increasing responsibility at FormFactor Inc., or FormFactor, a publicly-traded semiconductor technology company, serving most recently as Senior Director of Product Management. Dr. Hobbs received his B.A. in Liberal Arts, with minors in Mathematics and Physics from Saint Mary’s College of California, his B.S. in Mechanical Engineering from the University of Southern California, and his M.S. and Ph.D. in Mechanical Engineering, Microelectromechanical Systems, from the University of California, Berkeley.- EricD.Hobbs自2017年3月以来一直担任我们的董事会成员和首席执行官。此前，霍布斯博士曾于2016年3月至2017年3月担任我们的高级副总裁，运营和消耗品，于2015年2月至2016年3月担任我们的Vice President，运营和消耗品，并于2013年5月至2015年2月担任研究与开发高级总监。在Berkeley Lights之前，霍布斯博士在FormFactor公司或FormFactor公司（一家公开上市的半导体技术公司）担任越来越重要的职务，最近担任产品管理高级主管。Hobbs博士在加州圣玛丽学院（Saint Mary&8217；s College of California）获得文科学士学位，并辅修数学和物理，在南加州大学（University of Southern California）获得机械工程学士学位，在加州大学伯克利分校（University of California，Berkeley）获得微机电系统机械工程硕士学位和博士学位。
- Eric D. Hobbs has served as a member of our board of directors and as our Chief Executive Officer since March 2017. Previously, Dr. Hobbs served as our Senior Vice President, Operations and Consumables, from March 2016 to March 2017 as our Vice President, Operations and Consumables, from February 2015 to March 2016 and as Senior Director, Research and Development, from May 2013 until February 2015. Prior to Berkeley Lights, Dr. Hobbs held roles of increasing responsibility at FormFactor Inc., or FormFactor, a publicly-traded semiconductor technology company, serving most recently as Senior Director of Product Management. Dr. Hobbs received his B.A. in Liberal Arts, with minors in Mathematics and Physics from Saint Mary’s College of California, his B.S. in Mechanical Engineering from the University of Southern California, and his M.S. and Ph.D. in Mechanical Engineering, Microelectromechanical Systems, from the University of California, Berkeley.
- Shaun M. Holt
ShaunM.Holt自2016年3月起担任我们的首席财务官。此前，霍尔特先生曾于2015年11月至2016年3月担任我们的Vice President兼财务和会计主管。霍尔特此前曾于2008年7月至2015年11月在Illumina，Inc.担任多个财务领导职位，该公司是一家上市的生命科学分析公司，包括高级董事、全球业务单元和研究与开发财务主管、财务主管以及欧洲、中东和非洲地区财务与会计主管，以及商业财务规划和分析主管。2005年6月至2008年7月，霍尔特先生还担任过Websense，Inc.的财务规划和分析经理。Holt从2004年到2005年担任Kyocera Communications，Inc.高级金融分析师，从2001年到2004年担任Macromedia，Inc.成本会计、成本分析师和金融分析师。Holt先生在加州州立大学斯坦尼斯劳斯分校（California State University，Stanislaus）获得金融学士学位。
Shaun M. Holt has served as our Chief Financial Officer since March 2016. Previously, Mr. Holt served as our Vice President, Head of Finance and Accounting from November 2015 to March 2016. Mr. Holt previously served in a variety of finance leadership roles at Illumina, Inc., a publicly traded life sciences analytics company, from July 2008 until November 2015 including Senior Director, Head of Finance, Global Business Units and Research and Development, Finance Director, Head of EMEA Finance & Accounting, and Head of Commercial Financial Planning and Analysis. Mr. Holt also previously served as Manager of Financial Planning and Analysis at Websense, Inc. from June 2005 until July 2008. Mr. Holt was a Senior Financial Analyst at Kyocera Communications, Inc. from 2004 to 2005 and Cost Accountant, Cost Analyst and Financial Analyst at Macromedia, Inc. from 2001 to 2004. Mr. Holt received his B.B.A. in Finance from California State University, Stanislaus.- ShaunM.Holt自2016年3月起担任我们的首席财务官。此前，霍尔特先生曾于2015年11月至2016年3月担任我们的Vice President兼财务和会计主管。霍尔特此前曾于2008年7月至2015年11月在Illumina，Inc.担任多个财务领导职位，该公司是一家上市的生命科学分析公司，包括高级董事、全球业务单元和研究与开发财务主管、财务主管以及欧洲、中东和非洲地区财务与会计主管，以及商业财务规划和分析主管。2005年6月至2008年7月，霍尔特先生还担任过Websense，Inc.的财务规划和分析经理。Holt从2004年到2005年担任Kyocera Communications，Inc.高级金融分析师，从2001年到2004年担任Macromedia，Inc.成本会计、成本分析师和金融分析师。Holt先生在加州州立大学斯坦尼斯劳斯分校（California State University，Stanislaus）获得金融学士学位。
- Shaun M. Holt has served as our Chief Financial Officer since March 2016. Previously, Mr. Holt served as our Vice President, Head of Finance and Accounting from November 2015 to March 2016. Mr. Holt previously served in a variety of finance leadership roles at Illumina, Inc., a publicly traded life sciences analytics company, from July 2008 until November 2015 including Senior Director, Head of Finance, Global Business Units and Research and Development, Finance Director, Head of EMEA Finance & Accounting, and Head of Commercial Financial Planning and Analysis. Mr. Holt also previously served as Manager of Financial Planning and Analysis at Websense, Inc. from June 2005 until July 2008. Mr. Holt was a Senior Financial Analyst at Kyocera Communications, Inc. from 2004 to 2005 and Cost Accountant, Cost Analyst and Financial Analyst at Macromedia, Inc. from 2001 to 2004. Mr. Holt received his B.B.A. in Finance from California State University, Stanislaus.
- Keith J. Breinlinger
KeithJ.Breinlinger自2013年3月以来一直担任我们的首席技术官。此前，Breinlinger从2005年7月到2013年3月担任FormFactor产品和系统架构师，从1996年到2005年担任Teradyne机械架构师。从1993年到1995年，Breinlinger博士是iRobot的机械设计师。Breinlinger博士在麻省理工学院（Massachusetts Institute of Technology）获得机械工程学士学位、硕士学位和博士学位。
Keith J. Breinlinger has served as our Chief Technology Officer since March 2013. Previously, Dr. Breinlinger was a Product and System Architect at FormFactor from July 2005 until March 2013 and a Mechanical Architect at Teradyne from 1996 to 2005. From 1993 until 1995 Dr. Breinlinger was a Mechanical Designer at iRobot. Dr. Breinlinger received his B.S., M.S. and Ph.D. in Mechanical Engineering from the Massachusetts Institute of Technology.- KeithJ.Breinlinger自2013年3月以来一直担任我们的首席技术官。此前，Breinlinger从2005年7月到2013年3月担任FormFactor产品和系统架构师，从1996年到2005年担任Teradyne机械架构师。从1993年到1995年，Breinlinger博士是iRobot的机械设计师。Breinlinger博士在麻省理工学院（Massachusetts Institute of Technology）获得机械工程学士学位、硕士学位和博士学位。
- Keith J. Breinlinger has served as our Chief Technology Officer since March 2013. Previously, Dr. Breinlinger was a Product and System Architect at FormFactor from July 2005 until March 2013 and a Mechanical Architect at Teradyne from 1996 to 2005. From 1993 until 1995 Dr. Breinlinger was a Mechanical Designer at iRobot. Dr. Breinlinger received his B.S., M.S. and Ph.D. in Mechanical Engineering from the Massachusetts Institute of Technology.
- Stuart L. Merkadeau
自2003年10月起Stuart L. Merkadeau 任我们的高级副总裁。自2002年10月起，任总法律顾问和秘书。从2002年10月至2003年9月，他曾任副总裁之一。 从2000年7月至2002年10月，任 Intellectual Property 副总裁。 从1990年到2000年7月，他从事法律工作并任 法律顾问，之后任 Graham & James LLP的合伙人 在那里他专门从事知识产权事务授权和战略咨询服务。 在美国专利和商标局前，他获得在加州执业的准许，注册执业。 他持有西北大学工业工程 学士学位和加州大学洛杉矶分校法学博士。
Stuart L. Merkadeau has served as our General Counsel since June 2015. Mr. Merkadeau previously served as Senior Vice President, General Counsel and Corporate Secretary of FormFactor from October 2002 until May 2015 and as Vice President, Intellectual Property of FormFactor from July 2000 to September 2002. Prior to this, Mr. Merkadeau was a partner at Graham & James LLP, a private law firm, where he oversaw a variety of licensing, corporate, and litigation matters across a broad range of technologies. Mr. Merkadeau received his B.S. in Industrial Engineering from Northwestern University and his J.D. from the University of California, Los Angeles School of Law. He is admitted to practice law in California and is registered before the U.S. Patent and Trademark Office.- 自2003年10月起Stuart L. Merkadeau 任我们的高级副总裁。自2002年10月起，任总法律顾问和秘书。从2002年10月至2003年9月，他曾任副总裁之一。 从2000年7月至2002年10月，任 Intellectual Property 副总裁。 从1990年到2000年7月，他从事法律工作并任 法律顾问，之后任 Graham & James LLP的合伙人 在那里他专门从事知识产权事务授权和战略咨询服务。 在美国专利和商标局前，他获得在加州执业的准许，注册执业。 他持有西北大学工业工程 学士学位和加州大学洛杉矶分校法学博士。
- Stuart L. Merkadeau has served as our General Counsel since June 2015. Mr. Merkadeau previously served as Senior Vice President, General Counsel and Corporate Secretary of FormFactor from October 2002 until May 2015 and as Vice President, Intellectual Property of FormFactor from July 2000 to September 2002. Prior to this, Mr. Merkadeau was a partner at Graham & James LLP, a private law firm, where he oversaw a variety of licensing, corporate, and litigation matters across a broad range of technologies. Mr. Merkadeau received his B.S. in Industrial Engineering from Northwestern University and his J.D. from the University of California, Los Angeles School of Law. He is admitted to practice law in California and is registered before the U.S. Patent and Trademark Office.